Peter Hotez, MD, PhD, dean, Nationwide Faculty of Tropical Drugs, Baylor Faculty of Drugs; co-director, Middle for Vaccine Growth, Texas Kids’s Hospital, Houston.

Paul Offit, MD, director, Vaccine Training Middle and professor of pediatrics, Kids’s Hospital of Philadelphia.

Michael T. Osterholm, PhD, director, Middle for Infectious Illness Analysis and Coverage (CIDRAP), College of Minnesota, Minneapolis.

Floor Truths. Eric Topol, MD: “The bivalent vaccine booster outperforms.” 

CDC: “COVID Information Tracker: Weekly Overview,” “Charges of Laboratory-Confirmed COVID-19 Hospitalizations by Vaccination Standing,” “Pattern within the Variety of COVID-19 Vaccinations within the U.S.”

FDA: “Vaccine and Associated Organic Merchandise Advisory Committee January 26 Assembly Announcement.”

The New England Journal of Drugs: “Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters,” “Antibody Response to Omicron BA.4-BA.5 Bivalent Booster,” “Neutralization in opposition to BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster,” “Bivalent Covid-19 Vaccines – A Cautionary Story.”

Nature Drugs: “Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.”

BioRxiv: “Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants,” “Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine.”

Kaiser Household Basis: “ How A lot May COVID-19 Vaccines Value the U.S. After Commercialization?”

Alison Chartan, spokesperson, Novavax.

Pfizer Media Relations.

Supply hyperlink